1. Home
  2. USIO vs CRDF Comparison

USIO vs CRDF Comparison

Compare USIO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

HOLD

Current Price

$2.09

Market Cap

58.5M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USIO
CRDF
Founded
1998
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.5M
67.1M
IPO Year
1999
2012

Fundamental Metrics

Financial Performance
Metric
USIO
CRDF
Price
$2.09
$0.87
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$5.92
★ $6.28
AVG Volume (30 Days)
207.6K
★ 346.5K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ 0.02
N/A
Revenue
★ $28,200,535.00
$365,993.00
Revenue This Year
$14.36
N/A
Revenue Next Year
$12.26
$5.62
P/E Ratio
$102.25
★ N/A
Revenue Growth
12.69
★ 49.61
52 Week Low
$1.03
$0.71
52 Week High
$3.29
$3.31

Technical Indicators

Market Signals
Indicator
USIO
CRDF
Relative Strength Index (RSI) 29.78 49.18
Support Level $1.10 $0.77
Resistance Level $3.08 $1.13
Average True Range (ATR) 0.23 0.07
MACD -0.13 0.01
Stochastic Oscillator 9.70 68.37

Price Performance

Historical Comparison
USIO
CRDF

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: